Welcome to our dedicated page for Ceribell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. (CBLL) reported insider transactions by Chief Financial Officer Scott Blumberg on August 18–19, 2026. Blumberg exercised stock options covering 34,502 shares of common stock at exercise prices of $4.70 and $9.41 per share, then sold 34,502 shares of common stock at prices around $25 per share, including a weighted average sale price of $25.03. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025.
Ceribell, Inc. (symbol: CBLL) is the issuer of record for a Form 4/A filing submitted to the SEC.
Ceribell, Inc. (CBLL) reported that President and CEO Chao Xingjuan sold a total of 33,614 shares of common stock in open-market transactions on August 18–19, 2026, at prices around $25 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan. Xingjuan also reported an indirect holding of 369,088 shares of common stock held by the ACP 2021 Trust, where she is a co-trustee and disclaims beneficial ownership except to the extent of her pecuniary interest. The August 19 sale price is disclosed as a weighted average with individual trade prices ranging from $25.00 to $25.30.
Ceribell, Inc. (CBLL) is the issuer for a planned resale of its common stock by officer Scott E. Blumberg under Rule 144. The notice covers up to 33,512 shares of common stock to be sold through Fidelity Brokerage Services LLC, following acquisition via a stock option exercise for cash. The filing also lists prior sales of smaller share amounts by Blumberg within the preceding three months.
Ceribell, Inc. (CBLL) is the issuer for a planned resale of its common stock under Rule 144 by security holder Xingjuan Chao, using Fidelity Brokerage Services LLC as broker. The notice covers a proposed sale of 31,415 shares of common stock, with an aggregate market value of $786,364.46, when 38,378,101 shares of this class were outstanding as of 08/19/2026.
The shares to be sold were acquired through a stock option exercise on 04/30/2018, for cash, from the issuer. The filing also lists several prior sales of Ceribell common stock by Xingjuan Chao during the past three months, reflecting ongoing liquidity activity by this holder.
Ceribell, Inc. (CBLL) is the issuer in a notice under Rule 144 filed for planned sales of its common stock by holder Xingjuan Chao. The filing lists an upcoming transaction involving 2,199 shares of common stock associated with a stock option exercise, with Fidelity Brokerage Services LLC identified as the broker.
The notice also reports prior sales of Ceribell common stock by the same holder over the last three months, including 6,030 shares sold on May 21, 2026, and three separate blocks of 39,000 shares each sold on June 8, July 7, and August 3, 2026, with corresponding dollar amounts disclosed for each sale. The form is signed by an authorized representative of Fidelity Brokerage Services LLC acting as attorney-in-fact for the selling holder.
Ceribell, Inc. (CBLL) is the issuer of common stock that an affiliate, Scott E. Blumberg, has notified for potential sale under Rule 144. The notice covers 990 shares of common stock to be sold through Fidelity Brokerage Services LLC on or after 08/18/2026, with an indicated value of $24,750.00. The shares are to be acquired via a stock option exercise from the issuer for cash. In the prior three months, Blumberg previously sold 1,387 shares of Ceribell common stock on 05/21/2026 for proceeds of $24,960.31.
Ceribell, Inc. executive Xingjuan Chao, President and CEO, reported option exercises on August 13, 2026. She exercised stock options for 8,096 shares of common stock at an exercise price of $2.24 per share and for 25,000 shares at $3.65 per share, converting derivative awards into common stock. A separate holding entry shows 369,088 shares of common stock held indirectly by the ACP 2021 Trust, where she is co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership except to the extent of her pecuniary interest.
Ceribell, Inc. received an amended Schedule 13G/A reporting that investment entities affiliated with TPG GP A, LLC, together with James G. Coulter and Jon Winkelried, collectively report beneficial ownership of 2,975,566 shares of Ceribell common stock. These shares are held directly by The Rise Fund Clearthought, L.P., over which TPG GP A exercises indirect control. Based on 38,378,101 shares of common stock outstanding as of August 6, 2026, the reported stake represents 7.8% of Ceribell’s common stock. The reporting persons share voting and dispositive power over these shares and disclaim beneficial ownership except to the extent of any pecuniary interest.
Ceribell, Inc. director Joseph Michael Taylor reported a sale of common stock. On 2026-08-13, he sold 13,095 shares of Ceribell common stock in a sale categorized as an open market or private transaction at $23.40 per share. Following this transaction, he directly holds 48,478 shares of Ceribell common stock.